Wells Fargo Initiates Coverage On Karuna Therapeutics with Overweight Rating, Announces Price Target of $225
Portfolio Pulse from richadhand@benzinga.com
Wells Fargo analyst Mark Hughes has initiated coverage on Karuna Therapeutics (NASDAQ:KRTX) with an Overweight rating and a price target of $225.
August 22, 2023 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Karuna Therapeutics has received an Overweight rating from Wells Fargo with a price target of $225.
The Overweight rating from Wells Fargo indicates a positive outlook for Karuna Therapeutics. The price target of $225 suggests a significant upside potential from the current price. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100